| Accrued Liabilities and other Long-Term Liabilities |
11. Accrued Liabilities and other Long-Term Liabilities
Accrued expenses and other long-term liabilities consisted of the following:
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
($ in thousands) |
|
2021 |
|
2020 |
|
|
(Unaudited) |
|
|
|
Accrued expenses: |
|
|
|
|
|
|
Professional fees |
|
$ |
1,592 |
|
$ |
1,236 |
Salaries, bonus and related benefits |
|
|
5,983 |
|
|
6,701 |
Research and development |
|
|
4,234 |
|
|
5,007 |
Research and development - manufacturing |
|
|
— |
|
|
518 |
Research and development - license maintenance fees |
|
|
564 |
|
|
461 |
Research and development - milestones |
|
|
600 |
|
|
600 |
Accrued royalties payable |
|
|
2,048 |
|
|
2,682 |
Accrued coupon expense |
|
|
10,944 |
|
|
10,869 |
Other |
|
|
1,846 |
|
|
1,188 |
Total accrued expenses |
|
$ |
27,811 |
|
$ |
29,262 |
|
|
|
|
|
|
|
Other long-term liabilities: |
|
|
|
|
|
|
Deferred rent and long-term lease abandonment charge1 |
|
$ |
1,903 |
|
$ |
1,949 |
Partner company note payable, long-term: |
|
|
|
|
|
|
Ximino agreement2 |
|
|
3,790 |
|
|
3,622 |
Isotretinoin agreement3 |
|
|
1,823 |
|
|
2,792 |
Anti-itch product agreement4 |
|
|
— |
|
|
945 |
Total other long-term liabilities and partner company note payable, long-term |
|
$ |
7,516 |
|
$ |
9,308 |
Note 1: |
As of March 31, 2021, and December 31, 2020, the balance consists of deferred charges related to build-out of the New York facility. |
Note 2: |
As of March 31, 2021, and December 31, 2020, the imputed interest discount was $1.2 million and $1.4 million, respectively, in connection with its acquisition of Ximino in July 2019. As of March 31, 2021, and December 31, 2020, $2.0 million and $2.0 million, respectively, of note payable was classified as short-term. |
Note 3: |
As of March 31, 2021, and December 31, 2020, the imputed discount balance was $0.2 million and $0.2 million, respectively. The imputed interest discount was calculated utilizing a 4.00% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of March 31, 2021, and December 31, 2020, $1.5 million and $0.5 million, respectively, of note payable was classified as short-term. |
Note 4: As of March 31, 2021, and December 31, 2020, the imputed discount balance was approximately $37,000 and $0.1 million, respectively in connection with its acquisition of an anti-itch product. The imputed interest discount was calculated utilizing a 4.25% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of March 31, 2021, and December 31, 2020, $2.0 million and $2.8 million, respectively, of note payable was classified as partner company note payable, short-term on the Company’s Condensed Consolidated Balance Sheet.
|